Comparative Preclinical Pharmacokinetics and Bioavailability of Antidepressant GSB-106 Tablet Form
- 6 Downloads
Pharmacokinetics and relative bioavailability of antidepressant GSB-106 (hexamethylendiamide bis-(N-monosuccinyl-L-seryl-L-lysine) were determined in rabbits after single oral administration of the pharmaceutical substance and tablet mass. GSB-106 concentrations in the blood plasma were determined by HPLC-mass spectrometry. Relative bioavailability of GSB-106 tablet form was 160.79±24.33%.
Key Wordsantidepressant GSB-106 preclinical pharmacokinetics HPLC-MS
Unable to display preview. Download preview PDF.
- 1.Bardakov AI, Litvin AA, Slivkin AI. Biopharmaceutical Approaches in the Development and Testing of Finished Dosage Forms. Voronezh, 2010. Russian.Google Scholar
- 2.Gribakina OG, Bochkov PO, Shevchenko RV, Zherdev VP. Validation of the method of quantitative HPLC/MS assay of GSB-106 compound in rat blood plasma. Eksp. Klin. Farmakol. 2018;81(S):60-61. Russian.Google Scholar
- 3.Zherdev VP, Boyko SS, Shevchenko RV, Gudasheva TA. The Role of pharmacokinetics and biopharmaceutical investigations in the creation of a new dipeptide drugs (experimental investigation). Farmakokinetika Farmakodinamika. 2017;(1):3-10. Russian.Google Scholar
- 4.Seredenin SB, Gudasheva TA. Patent RU No. 2410392. Dipeptide mimetics of NGF and BDNF neurotrophins. Bull. No. 3. Published January 27, 2011.Google Scholar